Week 24 results: GNBAC1 in RRMS (GNC-003, change-MS; Clinical trial assessing the herv-W env antagonist GNBAC1 for efficacy in MS)

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2018
This article has no abstract
Epistemonikos ID: 4693235fb549e03225a7d2bc1b3c02ec355b023c
First added on: Apr 29, 2026